The CASCADE Study [COVID-19]
Research type
Research Study
Full title
Measures of complement activation and inflammation in patients with coronavirus disease 2019
IRAS ID
282013
Contact name
Anoop Chauhan
Contact email
Sponsor organisation
Portsmouth Hospitals NHS Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Covid-19 is a new infectious disease caused by a recently discovered coronavirus, SARS-CoV-2. It first appeared in Wuhan, China in December 2019 and has since spread around the world. Most people who are infected with the virus experience mild to moderate symptoms and recover without needing to come to hospital for treatment. Of those people who do need to be admitted to hospital, the majority get better; however some may need oxygen or support with their breathing in order to get better. Unfortunately though there are some people who do not get better.\n\nCovid-19 is a new disease and therefore it is still not clear exactly how the virus affects the body and why people are affected so differently. In some cases, the virus causes a lot of inflammation in the lungs making it difficult to breath but it is not well understood how this happens or how best to treat this. \n\nThis study will investigate markers of inflammation, coagulation and complement activation (part of the inflammatory process) to see whether these levels are higher in patients with COVID-19 and whether these levels change with differing severity of respiratory failure. This will allow us to better understand how the virus effects the body and why it effects people differently. It may identify potential targets for treatment for patients with COVID-19. \n\nWe will recruit 100 participants from Queen Alexandra Hospital, Portsmouth with COVID-19 and respiratory failure (stratified by mild, moderate and severe). Blood samples will be taken to measure markers of complement activation, inflammation and coagulation and compare the differences to levels seen in healthy volunteers. In a subgroup of participants we will repeat their blood sampling sequentially if there is any deterioration in their respiratory failure.
REC name
South Central - Berkshire Research Ethics Committee
REC reference
20/SC/0228
Date of REC Opinion
20 May 2020
REC opinion
Favourable Opinion